Iron mediates neuritic tree collapse in mesencephalic neurons treated with 1-methyl-4-phenylpyridinium (MPP+)

Journal of Neural Transmission

Volumn 118, Issue 3, 2011, Pages 421-431

  Gómez, Francisco J ^a   Aguirre, Pabla ^a   Gonzalez Billault, Christian ^a   Núñez, Marco T ^a  

^a UNIVERSITY OF CHILE   (Chile)

Author keywords

Antioxidants; Complex I; Glutathione; Iron; Parkinson

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; BUTHIONINE SULFOXIMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE; IRON; OXIDOPAMINE; DOPAMINE;

ARTICLE; CELL DEATH; CONFOCAL LASER SCANNING MICROSCOPY; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNOCYTOCHEMISTRY; LAPAROTOMY; MESENCEPHALON; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; ANALYSIS OF VARIANCE; ANIMAL; CELL CULTURE; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; METABOLISM; NERVE CELL; NEURITE; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANALYSIS OF VARIANCE; ANIMALS; CELL DEATH; CELLS, CULTURED; DOPAMINE; IMMUNOHISTOCHEMISTRY; IRON; MESENCEPHALON; NEURITES; NEURONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 80051617156     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0489-1     Document Type: Article

References (57)

1. Arredondo M, Martinez R, Núñez MT, Ruz M, Olivares M (2006) Inhibition of iron and copper uptake by iron, copper and zinc. Biol Res 39(1):95–102
2. Baloyannis SJ (2009) Dendritic pathology in Alzheimer’s disease. J Neurol Sci 283(1–2):153–157
3. Baloyannis SJ, Costa V, Baloyannis IS (2006) Morphological alterations of the synapses in the locus coeruleus in Parkinson’s disease. J Neurol Sci 248(1–2):35–41
4. Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson’s disease pathogenesis. Biochim Biophys Acta 1792(7):651–663
5. Berg D, Youdim MB (2006) Role of iron in neurodegenerative disorders. Top Magn Reson Imaging 17(1):5–17
6. Borquez D, Valdés P, Núñez MT (2008) Iron toxicity: a critical review on its role in Parkinson’s disease. In: Von Bernhardi R, Inestrosa NC (eds) Neurodegenerative diseases: from molecular concepts to therapeutic targets. Nova Science Publishers, Inc., Hauppauge, New York, pp 189–204
7. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10(Suppl):S2–S9
8. Brouard A, Pelaprat D, Dana C, Vial M, Lhiaubet AM, Rostene W (1992) Mesencephalic dopaminergic neurons in primary cultures express functional neurotensin receptors. J Neurosci 12(4): 1409–1415
9. Capetillo-Zarate E, Staufenbiel M, Abramowski D, Haass C, Escher A, Stadelmann C, Yamaguchi H, Wiestler OD, Thal DR (2006) Selective vulnerability of different types of commissural neurons for amyloid beta-protein-induced neurodegeneration in APP23 mice correlates with dendritic tree morphology. Brain 129(Pt 11):2992–3005
10. Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK (2006) Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson’s disease. Free Radic Biol Med 40(9): 1557–1563
11. Cleeter MWJ, Schapira AH (1992) Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine: evidence for free radical involvement. J Neurochem 58(2):786–789
12. Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6(11):889–898
13. Coombs JL, Van Der List D, Chalupa LM (2007) Morphological properties of mouse retinal ganglion cells during postnatal development. J Comp Neurol 503(6):803–814
14. D’Alessio M, Cerella C, Amici C, Pesce C, Coppola S, Fanelli C, De Nicola M, Cristofanon S, Clavarino G, Bergamaschi A, Magrini A, Gualandi G, Ghibelli L (2004) Glutathione depletion up-reg-ulates Bcl-2 in BSO-resistant cells. Faseb J 18(13):1609–1611
15. Del Zompo MPM, Ruiu S, Quartu M, Gessa GL, Vaccari A (1993) Selective uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. Br J Pharmacol 109(2):411–414
16. Engele J, Rieck H, Choi-Lundberg D, Bohn MC (1996) Evidence for a novel neurotrophic factor for dopaminergic neurons secreted from mesencephalic glial cell lines. J Neurosci Res 43(5): 576–586
17. Fiala JC, Spacek J, Harris KM (2002) Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev 39(1):29–54
18. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ (2003) Nigral glutathione deficiency is not specific for idiopathic Parkinson’s disease. Mov Disord 18(9):969–976
19. Gulledge AT, Kampa BM, Stuart GJ (2005) Synaptic integration in dendritic trees. J Neurobiol 64(1):75–90
20. Halliwell B (2006) Reactive species and antioxidants Redox biology is a fundamental theme of aerobic life. Plant Physiol 141(2):312–322
21. Hattingen E, Magerkurth J, Pilatus U, Mozer A, Seifried C, Steinmetz H, Zanella F, Hilker R (2009) Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson’s disease. Brain 132(Pt 12):3285–3297
22. Jenner P, Olanow CW (1998) Understanding cell death in Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S72–S84
23. Jenner P, Olanow CW (2006) The pathogenesis of cell death in Parkinson’s disease. Neurology 66(10 Suppl 4):S24–S36
24. Johnston D, Magee JC, Colbert CM, Cristie BR (1996) Active properties of neuronal dendrites. Annu Rev Neurosci 19:165–186
25. Kalivendi SV, Kotamraju S, Cunningham S, Shang T, Hillard CJ, Kalyanaraman B (2003) 1-Methyl-4-phenylpyridinium (MPP+)-induced apoptosis and mitochondrial oxidant generation: role of transferrin-receptor-dependent iron and hydrogen peroxide. Biochem J 371(Pt 1):151–164
26. Kienzl E, Jellinger K, Stachelberger H, Linert W (1999) Iron as catalyst for oxidative stress in the pathogenesis of Parkinson’s disease? Life Sci 65(18–19):1973–1976
27. Mandel SA, Fishman T, Youdim MB (2007) Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat Disord 13(Suppl 3):S242–S247
28. Mayer RA, Kindt MV, Heikkila RE (1986) Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport. J Neurochem 47(4):1073–1079
29. McNeill TH, Brown SA, Rafols JA, Shoulson I (1988) Atrophy of medium spiny I striatal dendrites in advanced Parkinson’s disease. Brain Res 455(1):148–152
30. Meister A, Anderson ME (1983) Glutathione. Annu Rev Biochem 52:711–760
31. Mena NP, Esparza A, Tapia V, Valdes P, Núñez MT (2008) Hepcidin inhibits apical iron uptake in intestinal cells. Am J Physiol Gastrointest Liver Physiol 294(1):G192–G198
32. Morfini G, Pigino G, Opalach K, Serulle Y, Moreira JE, Sugimori M, Llinas RR, Brady ST (2007) 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C. Proc Natl Acad Sci USA 104(7):2442–2447
33. Nicklas WJ, Youngster SK, Kindt MV, Heikkila RE (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40(8):721–729
34. Núñez MT, Tapia V (1999) Transferrin stimulates iron absorption, exocytosis, and secretion in cultured intestinal cells. Am J Physiol 276(5 Pt 1):C1085–C1090
35. Núñez MT, Gallardo V, Muñoz P, Tapia V, Esparza A, Salazar J, Speisky H (2004) Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells. Free Radic Biol Med 37(7):953–960
36. Paris I, Martinez-Alvarado P, Cardenas S, Perez-Pastene C, Grau-mann R, Fuentes P, Olea-Azar C, Caviedes P, Segura-Aguilar J (2005) Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 18(3):415–419
37. Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33(3):305–310
38. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, Smith MA (2003) Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16(1):77–81
39. Przedborski S, Vila M (2003) The 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine mouse model: a tool to explore the pathogenesis of Parkinson’s disease. Ann N Y Acad Sci 991:189–198
40. Sayre LM, Perry G, Atwood CS, Smith MA (2000) The role of metals in neurodegenerative diseases. Cell Mol Biol (Noisy-le-grand) 46(4):731–741
41. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54(3):823–827
42. Scotcher KP, Irwin I, DeLanney LE, Langston JW, Di Monte D (1990) Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on ATP levels of mouse brain synaptosomes. J Neurochem 54(4):1295–1301
43. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36(3):348–355
44. Smeyne RJ, Jackson-Lewis V (2005) The MPTP model of Parkinson’s disease. Brain Res Mol Brain Res 134(1):57–66
45. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74(3):199–205
46. Solis O, Limon DI, Flores-Hernandez J, Flores G (2007) Alterations in dendritic morphology of the prefrontal cortical and striatum neurons in the unilateral 6-OHDA-rat model of Parkinson’s disease. Synapse 61(6):450–458
47. Stephens B, Mueller AJ, Shering AF, Hood SH, Taggart P, Arbuthnott GW, Bell JE, Kilford L, Kingsbury AE, Daniel SE, Ingham CA (2005) Evidence of a breakdown of corticostriatal connections in Parkinson’s disease. Neuroscience 132(3):741–754
48. Suzumura A, Takeuchi H, Zhang G, Kuno R, Mizuno T (2006) Roles of glia-derived cytokines on neuronal degeneration and regeneration. Ann N Y Acad Sci 1088:219–229
49. Takeuchi H, Mizuno T, Zhang G, Wang J, Kawanokuchi J, Kuno R, Suzumura A (2005) Neuritic beading induced by activated microglia is an early feature of neuronal dysfunction toward neuronal death by inhibition of mitochondrial respiration and axonal transport. J Biol Chem 280(11):10444–10454
50. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MM (2007) Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson’s disease: a dynamic model. Neuroscience 149(4):917–930
51. Vetter P, Roth A, Hausser M (2001) Propagation of action potentials in dendrites depends on dendritic morphology. J Neurophysiol 85(2):926–937
52. Weinreb O, Amit T, Mandel SA, Kupershmidt L, Youdim MB (2010) Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 13(6):919–949
53. Wong SS, Li RH, Stadlin A (1999) Oxidative stress induced by MPTP and MPP(+): selective vulnerability of cultured mouse astrocytes. Brain Res 836(1–2):237–244
54. Youdim MB (2008) Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res 14(1):45–56
55. Youdim MB, Riederer P (1997) Understanding Parkinson’s disease. Sci Am 276(1):52–59
56. Zaja-Milatovic S, Milatovic D, Schantz AM, Zhang J, Montine KS, Samii A, Deutch AY, Montine TJ (2005) Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 64(3):545–547
57. Zoccarato F, Toscano P, Alexandre A (2005) Dopamine-derived dopaminochrome promotes H(2)O(2) release at mitochondrial complex I: stimulation by rotenone, control by Ca(2+), and relevance to Parkinson disease. J Biol Chem 280(16): 15587–15594